Related CAS #
4675-90-5 (Na); 547-44-4 (free base)
Synonym
Sulfacarbamide; Uramid; Sulfanilylurea
IUPAC/Chemical Name
Benzenesulfonamide, 4-amino-N-(aminocarbonyl)- (9CI)
InChi Key
WVAKABMNNSMCDK-UHFFFAOYSA-N
InChi Code
InChI=1S/C7H9N3O3S/c8-5-1-3-6(4-2-5)14(12,13)10-7(9)11/h1-4H,8H2,(H3,9,10,11)
SMILES Code
O=S(C1=CC=C(N)C=C1)(NC(N)=O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
215.23
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Otto W, Woraschk HJ, Mlytz H. [Placental passage of sulfacarbamide]. Zentralbl Gynakol. 1971 Apr 24;93(17):552-7. German. PubMed PMID: 5577004.
2: Bruun JN, Ostby N, Bredesen JE, Kierulf P, Lunde PK. Sulfonamide and trimethoprim concentrations in human serum and skin blister fluid. Antimicrob Agents Chemother. 1981 Jan;19(1):82-5. PubMed PMID: 7247364; PubMed Central PMCID: PMC181361.
3: Kowalski P, Plenis A, Oledzka I, Konieczna L. Optimization and validation of the micellar electrokinetic capillary chromatographic method for simultaneous determination of sulfonamide and amphenicol-type drugs in poultry tissue. J Pharm Biomed Anal. 2011 Jan 5;54(1):160-7. doi: 10.1016/j.jpba.2010.08.005. Epub 2010 Aug 17. PubMed PMID: 20817447.
4: LANGECKER H, SCHULZE E. [Distribution of sulfanilic acid, sulfanilamide and sulfacarbamide in the blood, cerebrospinal fluid, aqueous humor and pericardial fluid in adrenalectomized dog. II. Dynamics of distribution]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1954;221(2):160-5. Undetermined Language. PubMed PMID: 13154430.
5: Bergan T, Bruun JN, Ostby N, Bredesen JE, Lunde PK. Human pharmacokinetics and skin blister levels of sulfonamides and dihydrofolate reductase inhibitors. Chemotherapy. 1986;32(4):319-28. PubMed PMID: 3731918.
6: Guldsten H. Clindamycin and sulphonamides in the treatment of ocular toxoplasmosis. Acta Ophthalmol (Copenh). 1983 Feb;61(1):51-7. PubMed PMID: 6858644.
7: Hładoń T. [Physico-chemical studies on adsorptive properties of pharmaceutic aids used in pharmaceutical technology. II. Mechanism of adsorption of sulfonamides on Veegum]. Acta Pol Pharm. 1981;38(2):229-35. Polish. PubMed PMID: 7315467.
8: PENCHEV I, POPOV A, KOLAROV P, ANDREEV D. [Sulfanilylurea therapy of diabetes mellitus]. Probl Endokrinol Gormonoter. 1958 Nov-Dec;4(6):20-8. Russian. PubMed PMID: 13633935.
9: POGOZHEVA LN. [Sulfanilylurea in the control of urinary infections]. Sov Med. 1951 Mar;3:23-4. Undetermined Language. PubMed PMID: 14817507.
10: Vicentini CB, Guarneri M, Sarto G. Hypoglycemic compounds. Sulfanilylurea derivatives containing amino acids and dipeptides. I. Farmaco Sci. 1983 Aug;38(8):595-602. PubMed PMID: 6617854.
11: BRETAN M, KAMMERER L. [Insulin-like activity of the plasma during Bucarban treatment. (Data on the mechanism of action of the sulfanilylureas)]. Orv Hetil. 1962 Oct 21;103:1981-5. Hungarian. PubMed PMID: 14015308.
12: Tret'iakova LF, Kochergin IuV. [Moderately mineralized (Obukhovskaia) mineral water and urosulfan electrophoresis in the treatment of children with pyelonephritis]. Vopr Kurortol Fizioter Lech Fiz Kult. 1984 Sep-Oct;(5):45-7. Russian. PubMed PMID: 6239446.
13: KALDOR A, POGATSA G. [The effect of sulfanilylurea preparations on the glucose release of the liver]. Orv Hetil. 1962 Oct 21;103:1985-6. Hungarian. PubMed PMID: 13961902.
14: Baranov VG, Gasparian EG. [Disputable problems of the effect of sulfanilylurea derivatives in patients with diabetes mellitus and perspectives on their use]. Probl Endokrinol (Mosk). 1983 Jan-Feb;29(1):3-7. Russian. PubMed PMID: 6340092.
15: DECOURTJUNIOR C. [EXPERIENCES WITH AN ASSOCIATION OF FORMO-PHTHALYL-SULFANILYLUREA AND NEOMYCIN IN INTESTINAL THERAPY]. Hospital (Rio J). 1964 Jun;65:1225-36. Portuguese. PubMed PMID: 14172856.
16: WILD H, LINDEN HW. [Clinical observations on injuries to the peripheral nervous system and liver in diabetics receiving sulfanilylurea]. Dtsch Med J. 1959 Jun 5;10(8):286-92. German. PubMed PMID: 13671990.
